FDA 执法报告 D-0165-2027 收录 Hikma 环丙沙星片亚硝胺超限的 Class II 自愿召回
FDA drug enforcement D-0165-2027: Hikma Pharmaceuticals USA INC. — CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.
FDA 执法报告 D-0165-2027 收录 Hikma Pharmaceuticals USA 对环丙沙星片 USP 500 mg 的 Class II 自愿召回,原因列为 CGMP 偏差,N-亚硝基环丙沙星结果超出 FDA 建议的临时控制限。
记录列出环丙沙星片因 N-亚硝基环丙沙星超出 FDA 建议临时控制限而由企业自愿召回,便于比对同类杂质的控制与分级信息。
FDA 药品召回执行报告 — D-0165-2027
报告发布日期:2026-11-11。这是执行报告的日期,不是召回启动日期。
范围:一条已分类的药品召回记录;event_id 可能归组多个产品。没有召回编号的未分类记录不在本数据流范围内。本记录不是新闻稿,也不是新的执法认定。
openFDA 数据集每周更新。报告状态不是实时召回状态,不得用于跟踪召回生命周期。以下其他日期保留其各自名称所表示的含义。
完整的官方产品记录(包括 openFDA 统一标识符):
{
"address_1": "1809 Wilson Rd",
"address_2": "",
"center_classification_date": "20261103",
"city": "Columbus",
"classification": "Class II",
"code_info": "Lot# CB496A; Exp. 12/31/2026 Lot# CB497A; Exp. 12/31/2026 Lot# CB498A; Exp. 12/31/2026",
"country": "United States",
"distribution_pattern": "US Nationwide",
"event_id": "100142",
"initial_firm_notification": "Letter",
"more_code_info": "",
"openfda": {
"application_number": [
"ANDA076558"
],
"brand_name": [
"CIPROFLOXACIN"
],
"generic_name": [
"CIPROFLOXACIN"
],
"is_original_packager": [
true
],
"manufacturer_name": [
"Hikma Pharmaceuticals USA Inc."
],
"package_ndc": [
"0143-9927-01",
"0143-9927-05",
"0143-9927-30",
"0143-9928-01",
"0143-9928-05",
"0143-9928-30",
"0143-9929-01",
"0143-9929-50"
],
"product_ndc": [
"0143-9928",
"0143-9927",
"0143-9929"
],
"product_type": [
"HUMAN PRESCRIPTION DRUG"
],
"route": [
"ORAL"
],
"rxcui": [
"197511",
"197512",
"309309"
],
"spl_id": [
"7caf3140-173f-4afa-8066-fb22953646c2"
],
"spl_set_id": [
"3b3d22dc-df09-4910-8c9b-1204eeedbd68"
],
"substance_name": [
"CIPROFLOXACIN HYDROCHLORIDE"
],
"unii": [
"4BA73M5E37"
]
},
"postal_code": "43228-9579",
"product_description": "Ciprofloxacin Tablets, USP, 500 mg, 100-count bottle, Rx Only, Manufactured by: Hikma Pharmaceuticals, P.O. Box 182400, Amman, 11118-Jordan, Distributed by: Hikma Pharmaceuticals USA Inc. Berkely Heights, NJ 07922, NDC 0143-9928-01",
"product_quantity": "29,085 bottles",
"product_type": "Drugs",
"reason_for_recall": "CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.",
"recall_initiation_date": "20261020",
"recall_number": "D-0165-2027",
"recalling_firm": "Hikma Pharmaceuticals USA INC.",
"report_date": "20261111",
"state": "OH",
"status": "Ongoing",
"voluntary_mandated": "Voluntary: Firm initiated"
}
来源:openFDA 已分级药品召回执法报告 · api.fda.gov